+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

ANDA Litigation and The America Invents Act - Webinar

  • ID: 3691045
  • Webinar
  • Region: United States
  • 90 Minutes
  • BDA/Business Development Academy
1 of 3
This session is critical for understanding how The America Invents Act will impact ANDA Litigation. This course provides a thorough review of Abbreviated New Drug Applications and AIA specific issues such as inter-partes review; post-grant review; supplemental examination; derivation proceedings; and, patent prosecution issues. The program concludes by delving into an analysis of recent litigation that intersects with the AIA and ANDA.

The following are among the issues discussed during this webinar:

What are the incentives for filing for ANDA?
How will interferences by impacted by the AIA?
Does the AIA raise or lower the bar for the issue of obviousness? How can potential obvious challenges be drafted around?
How does the AIA affect prior use defenses?
What is the status of the best mode requirement under the AIA?
What should you know about the intersection of prophetic experiment and the written description requirement?
What are the standards for pursuing post-grant review?
What role does lead compound analysis play in ANDA and patent challenges under the AIA?
What are the fee schedules like in terms of filing for inter-partes review and supplemental examinations?

The following are among the recent cases that are reviewed in detail:

Pfizer v. Apotex
Otsuka Pharma v. Sandoz
University of Rochester v. Pfizer
Ariad v. Eli Lilly
Caraco Pharma Labs., Ltd v. Novo Nordisk A/S
Note: Product cover images may vary from those shown
2 of 3


3 of 3
Robert D. Katz
Note: Product cover images may vary from those shown
4 of 3
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/3691045